Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ARG1 | P05089 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL30025576 | 1.00 | SLC6A4 (0.51) | SLC6A4ALDH1A1MAPTRECQLARG1 | |
| SCHEMBL18395931 | 0.96 | SLC6A4 (0.55) | SLC6A4ALDH1A1MAPTRECQLARG1 | |
| SCHEMBL20149705 | 0.96 | SLC6A4 (0.55) | SLC6A4ALDH1A1MAPTRECQLARG1 | |
| Phosphoric Acid SCHEMBL18396242 | 0.95 | SLC6A4 (0.48) | SLC6A4ALDH1A1MAPTRECQLARG1 | |
| Hydrochloric Acid SCHEMBL18395437 | 0.95 | SLC6A4 (0.56) | SLC6A4ALDH1A1MAPTRECQLARG1 | |
| Sulfuric Acid SCHEMBL18395716 | 0.92 | SLC6A4 (0.51) | SLC6A4ALDH1A1MAPTRECQLARG1 | |
| Sulfuric Acid SCHEMBL30025453 | 0.92 | SLC6A4 (0.51) | SLC6A4ALDH1A1MAPTRECQLARG1 | |
| Sulfuric Acid SCHEMBL22393227 | 0.92 | SLC6A4 (0.51) | SLC6A4ALDH1A1MAPTRECQLARG1 | |
| Sulfuric Acid SCHEMBL22393226 | 0.92 | SLC6A4 (0.51) | SLC6A4ALDH1A1MAPTRECQLARG1 | |
| Sulfuric Acid SCHEMBL18395715 | 0.92 | SLC6A4 (0.51) | SLC6A4ALDH1A1MAPTRECQLARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3613420-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3954369-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | Lumos Pharma, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3324958-B1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20200283385-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2020-09-10 | — | — | US | disclosed |
| EP-3613420-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | Newlink Genetics Corporation (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10207990-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2018-05-17 | — | — | US | disclosed |
| US-9732035-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | NEWLINK GENETICS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | LUMOS PHARMA, INC. | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10207990-B2 | Salts and prodrugs of 1-methyl-D-tryptophan | IDO1, IDO2, INMT | PIK3CD 1346/4885SLC6A4 21/4885ALDH1A1 634/4885 |
| US-20200283385-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | PIK3CD 1346/4885SLC6A4 21/4885ALDH1A1 634/4885 |
| US-20170022157-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | PIK3CD 1346/4885SLC6A4 21/4885ALDH1A1 634/4885 |
| US-20180134658-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | IDO1, IDO2, INMT | PIK3CD 1346/4885SLC6A4 21/4885ALDH1A1 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.